Navigation Links
Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
Date:6/15/2009

SAN DIEGO, June 15 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it will present preclinical data from its LPA1 receptor antagonist program on June 30, 2009 at the Federation of American Societies for Experimental Biology (FASEB) Summer Research Conference in Carefree, Arizona.

The LPA1 receptor is part of the Phosphatidic Acid/Lysophosphatidylcholine pathway, which among other things is associated with cell to cell communication. In recent studies, it has been shown to potentially play a role in fibrotic disease, specifically Idiopathic Pulmonary Fibrosis (IPF).

"Our data not only confirms that this pathway may play a role in fibrotic diseases such as IPF, but that we are well on our way to developing an orally available antagonist which could be studied in a human clinical setting," said Peppi Prasit, Ph.D., Chief Scientific Officer. "While a great deal of work remains on this program, we are particularly excited since we believe this could be a novel, first-in-class therapy."

Bob Baltera, Chief Executive Officer, added, "Our LPA1 program is particularly important for Amira. IPF is a specialty focused disease setting and presents the opportunity for Amira to develop a therapeutic through commercialization without the assistance of a strategic partner. Most importantly, IPF is a grievous disease with minimally effective therapeutic options for patients today."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

Amira has a partnership w
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
2. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
3. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
4. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
5. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
6. Amira Pharmaceuticals Appoints First Vice President of Development
7. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
8. Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study
9. Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo(R)
10. Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results
11. Isis Pharmaceuticals to Present at Jefferies 3rd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor Day weekend, the last ... on September 22nd this year). For IT security personnel, it should also mark the ... prove far more costly than a simple headache. , Joe Caruso, founder and CEO-CTO ...
(Date:8/29/2015)... Houston, TX (PRWEB) , ... August 29, 2015 ... ... settlement allows the company to freely market and sell Arterosil and Arterosil HP, ... Daniels Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the ...
(Date:8/28/2015)... ... 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth ... are applying for, they are unable to pass the initial drug test and therefore ... policies in order to be able to hire long-term, skilled talent. (1) Will Wesch, ...
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily on August ... for results that last for two years, the longest of any cellulite reduction system ... looking for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, ...
(Date:8/28/2015)... ... ... “ Frequentz ” was featured on NewsWatch as part of its monthly AppWatch, which ... Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the ... movement from beginning to end. , Businesses benefit greatly from having the ability to ...
Breaking Medicine News(10 mins):Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... ... facility, is announcing the launch of a state-of-the-art new website designed to mirror the ... the weight loss surgery process, and the latest tools of the web, the new site ... ...
... ... ), a privately held consulting company, announced today its marketing ... System solutions. Veracord,s comprehensive validation and compliance expertise extends the ... to compete in the FDA regulated industry. Together, Veracord and ...
... , , CHICAGO, Aug. ... scaly skin and rashes. It is commonly known as "the itch ... not known, it appears to result from a complex interaction of factors ... , Scratching the affected area can lead to more ...
... , , , ... Georgetown University Medical Center study find Kefir, a probiotic-rich drink, may ... experiencing health problems. In the study, the sickest children got the ... "We are happy to see that the 10 strains of good ...
... , WASHINGTON, Aug. 3 ... to Planned Parenthood President Cecile Richards to debate the question -- ... for abortion coverage and taxpayer funded abortions ? , ... Huffington Post, Planned Parenthood,s president states that the plan ...
... , , August is ... HARRISBURG, Pa., Aug. 3 Department of Health Secretary Everette ... National Immunization Awareness Month. , , "Recommended ... sure you and your family are up-to-date on these immunizations ...
Cached Medicine News:Health News:Tennessee's New Life Center for Bariatric Surgery Launches Comprehensive Website Reaching out to Sufferers of Morbid Obesity 2Health News:Tennessee's New Life Center for Bariatric Surgery Launches Comprehensive Website Reaching out to Sufferers of Morbid Obesity 3Health News:Tennessee's New Life Center for Bariatric Surgery Launches Comprehensive Website Reaching out to Sufferers of Morbid Obesity 4Health News:Veracord Delivers FDA Expertise with SyberWorks Latest Learning Management Solution 2Health News:Veracord Delivers FDA Expertise with SyberWorks Latest Learning Management Solution 3Health News:Veracord Delivers FDA Expertise with SyberWorks Latest Learning Management Solution 4Health News:Five Questions About Eczema 2Health News:Five Questions About Eczema 3Health News:Five Questions About Eczema 4Health News:Five Questions About Eczema 5Health News:Kefir, a Probiotic-Rich Drink, May Benefit Specific Groups of Children 2Health News:Corrected: Secretary of Health Urges Pennsylvanians to Get Immunized 2Health News:Corrected: Secretary of Health Urges Pennsylvanians to Get Immunized 3
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Tobramycin is a traditional antibiotic whose eye ... for the treatment of potential infection or inflammation caused ... China are able to produce tobramycin, ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
(Date:8/28/2015)...  IP Shakti, LLC, today announced that it has changed ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... identity signifies our transformation into a company focused on patent ... patent claim validity." ... Shield™ platform, the Company commenced a corporate re-branding initiative in ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... SARcode Corporation presented data today for their lead investigational ... trial, subjects receiving SAR 1118 demonstrated a reduction in ... as compared to placebo. These data were part of ... Vision and Ophthalmology (ARVO) Annual Meeting held in Fort ...
... 3, 2011 At the Board of Directors meeting held ... per share. The dividend is payable on June 15, 2011 ... About Sigma-Aldrich: Sigma-Aldrich is a leading ... to Improve the Quality of Life. Its chemical and biochemical ...
Cached Medicine Technology:SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 2SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: